Senate’s US FDA User Fee Bill Answers Biosimilar Interchangeable Exclusivity Questions
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.
The bill would allow for tentative interchangeable approvals, as well as shared first interchangeable exclusivity for multiple first filers.